|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
178,600,000 |
Market
Cap: |
253.61(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6736 - $2.03 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
23,588,234 |
25,180,265 |
Total Buy Value |
$0 |
$0 |
$20,049,999 |
$22,665,292 |
Total People Bought |
0 |
0 |
2 |
5 |
Total Buy Transactions |
0 |
0 |
2 |
8 |
Total Shares Sold |
0 |
0 |
0 |
455,706 |
Total Sell Value |
$0 |
$0 |
$0 |
$650,097 |
Total People Sold |
0 |
0 |
0 |
6 |
Total Sell Transactions |
0 |
0 |
0 |
21 |
End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shah Rutul R |
Chief Operating Officer |
|
2025-05-16 |
4 |
D |
$1.45 |
$84,239 |
D/D |
(58,096) |
403,959 |
|
- |
|
Shah Rutul R |
Chief Operating Officer |
|
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
174,460 |
462,055 |
|
- |
|
Tennant Phil |
Chief Commercial Officer |
|
2025-05-16 |
4 |
D |
$1.45 |
$33,305 |
D/D |
(22,969) |
59,031 |
|
- |
|
Tennant Phil |
Chief Commercial Officer |
|
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,441 |
82,000 |
|
- |
|
Sabzevari Helen |
President and CEO |
|
2025-05-16 |
4 |
D |
$1.45 |
$755,775 |
D/D |
(521,224) |
3,317,022 |
|
- |
|
Sabzevari Helen |
President and CEO |
|
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,079,137 |
3,838,246 |
|
- |
|
Thomasian Harry Jr. |
Chief Financial Officer |
|
2025-05-16 |
4 |
D |
$1.45 |
$74,589 |
D/D |
(51,441) |
457,410 |
|
- |
|
Thomasian Harry Jr. |
Chief Financial Officer |
|
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
154,475 |
508,851 |
|
- |
|
Lehr Donald P. |
Chief Legal Officer |
|
2025-05-16 |
4 |
D |
$1.45 |
$79,896 |
D/D |
(55,101) |
681,649 |
|
- |
|
Lehr Donald P. |
Chief Legal Officer |
|
2025-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
165,468 |
736,750 |
|
- |
|
Gupta Vinita D |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
576,240 |
|
- |
|
Kindler Jeffrey B |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
520,430 |
|
- |
|
Frank Steven |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
1,140,307 |
|
- |
|
Turley James S |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
595,772 |
|
- |
|
Alvarez Cesar L |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
693,264 |
|
- |
|
Hassan Fred |
Director |
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,412 |
1,153,452 |
|
- |
|
Kirk Randal J |
|
|
2025-03-14 |
4 |
OE |
$0.00 |
$0 |
I/I |
174,825 |
64,779,510 |
|
- |
|
Gupta Vinita D |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$62,998 |
D/D |
36,206 |
488,828 |
|
- |
|
Agee Nancy H |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$56,500 |
D/D |
32,471 |
50,076 |
|
- |
|
Kindler Jeffrey B |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$69,000 |
D/D |
39,655 |
433,018 |
|
- |
|
Frank Steven |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$49,999 |
D/D |
28,735 |
1,052,895 |
|
- |
|
Turley James S |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$62,499 |
D/D |
35,919 |
508,360 |
|
- |
|
Alvarez Cesar L |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$62,499 |
D/D |
35,919 |
605,852 |
|
- |
|
Hassan Fred |
Director |
|
2025-03-13 |
4 |
A |
$1.74 |
$62,998 |
D/D |
36,206 |
1,066,040 |
|
- |
|
Kirk Randal J |
|
|
2025-03-13 |
4 |
A |
$1.74 |
$100,000 |
I/I |
57,471 |
64,604,685 |
|
- |
|
631 Records found
|
|
Page 1 of 26 |
|
|